Tag: Biologics
Biocon & Biocon Biologics release their maiden integrated annual reports for...
Reports focus on their relentless pursuit to create sustainable value for the stakeholders
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
Biocon Biologics launches biosimilar ‘Hulio’ in USA
HULIO® (adalimumab-fkjp) injection, a biosimilar to Humira® (adalimumab) has been introduced in the United States after five years of experience in Europe and two years in Canada.
Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%
Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...
The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period
Biocon Biologics subsidiary enters Malaysia Book of Records
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia
US FDA issues observations for Biocon Biologics sites
At the conclusion of these inspections, the agency has issued Form 483s with 11 observations each for the two sites in Bengaluru and 6 observations for the Malaysia site
Juniper Biologics acquires cell-mediated gene therapy for treatment of knee osteoarthritis
The US$ 600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Lupin gets US-FDA nod for its Pegfilgrastim biosimilar application
The Biologics License Application (BLA) submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies........................
Biocon Biologics to offer its oncology biosimilars in over 30 countries
The company's agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars will enable access to Trastuzumab and Pegfilgrastim in Africa and Asia...................